---
schema_version: "secwatch.filing_event.v1"
accession: "0001636050-23-000011"
form_type: "8-K"
ticker: null
cik: "0001636050"
company_name: "Sio Gene Therapies Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:07:16.603545+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sio Gene Therapies receives Nasdaq delisting notice; will not appeal due to planned dissolution

## Summary
- Nasdaq notified Sio on March 14, 2023, that common stock will be delisted for failure to meet minimum bid price requirement.
- Company will not appeal the delisting determination in light of its planned complete liquidation and dissolution.
- Trading of Sio's common stock expected to be suspended at the open on March 23, 2023; Form 25-NSE to be filed.
- Dissolution plan is pending stockholder approval via proxy statement filed February 21, 2023, with SEC.

## SEC filing metadata
- accession: 0001636050-23-000011
- form_type: 8-K
- cik: 0001636050
- company_name: Sio Gene Therapies Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636050/000163605023000011/0001636050-23-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636050/000163605023000011/siox-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636050-23-000011
- JSON: https://secwatch.observer/filing/0001636050-23-000011.json
- Plain text: https://secwatch.observer/filing/0001636050-23-000011.txt

## Key facts
- Listing & Compliance Notices
  Sio Gene Therapies Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: March 14, 2023, the Company received written notice (the “ Delisting Notice ”) from Nasdaq notifying the Company that, as a result of its failure to regain compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company’s common stock will be delisted from the Nasdaq Capital Market. In light of the Company’s planned Dissolution, the Company will not appeal this determination. The Company expects, based on the Delisting Notice, that trading of the Company’s common stock will be suspended at the opening of business on March 23, 2023, and a Form 25-NSE will be filed with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636050/000163605023000011/0001636050-23-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.